3 R&D centres

Ipsen has set-up its R&D centres at the heart of three internationally reputed scientific hubs: Paris-Saclay in France, Oxford in the United Kingdom, and Cambridge in the United States. Each site is located close to leading academic research centres, cutting-edge medical centres and biotechnological companies. Interactions with key health industry players greatly increase our chances of access to innovative technologies to speed up the discovery and approval of drugs and services that improve the lives of patients.

 
The R&D centre at Les Ulis is located in the Paris-Saclay hub which is home to several thousand life sciences researchers. Ipsen’s innovation teams are housed in a high-tech environment, in close contact with major scientific and academic institutions, such as Ecole Polytechnique, the French National Center for Scientific Research (CNRS), the French National Institute of Health and Medical Research (INSERM) and the Atomic Energy Commission (CEA).

One of the missions of Ipsen’s largest R&D site, established in 1969, is to accelerate clinical development and fundamental research to deepen our understanding of molecular, pharmacological, pharmacodynamic and pharmacokinetic properties of new molecules in oncology and neurology.

Following through on its open innovation strategy, Ipsen teamed up with Aepodia in a partnership signed in January 2016 covering early-stage development programs in R&D. Aepodia will provide its expertise and agility in early clinical development and in the implementation of Phase I studies up to proof of concept (POC). Aepodia and Ipsen teams will work together to optimize the design of clinical studies and their operational implementation.

> 13%

of sales invested in R&D in 2015

3

global R&D centres

~300

employees assigned to R&D

Date of preparation January 2018 / ALL-UK-000455